{"url_path":"/sec/ssii/8-k/2026-07-14/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1676163/0001213900-26-077784-index.html","accession_number":"0001213900-26-077784","cik":"0001676163","ticker":"SSII","issuer_name":"SS Innovations International, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1676163/0001213900-26-077784-index.html","primary_entity_key":"0001676163","primary_entity_name":"SS Innovations International, Inc."},"word_count":829,"has_tables":true,"body_markdown":"false\n0001676163\n\n0001676163\n\n2026-07-14\n2026-07-14\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**Pursuant to Section 13 or 15(d) of The Securities\nExchange Act of 1934**\n\n \n\nDate of report (Date of earliest event reported):\n**July 14, 2026**\n\n \n\n**SS INNOVATIONS INTERNATIONAL, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Florida**\n \n**001-42615**\n \n**47-3478854**\n\n(State or Other Jurisdiction\n\nof Incorporation)\n \n(Commission File Number)\n \n(IRS Employer\n\nIdentification No.)\n\n \n\n**405, 3rd Floor****, iLabs Info Technology Centre**\n\n**Udyog Vihar, Phase III**\n\n******Gurugram****,\nHaryana India**\n\n \n**122016**\n\n(Address of Principal Executive Offices)\n \n(Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code: **+91 73375 53469**\n\n \n\n \n\n(Former name or former address, if changed since\nlast report)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General\nInstruction A.2. below):\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\n**Title\nof each Class**\n** **\n**Trading\nSymbol**\n** **\n**Name\nof each exchange on which registered**\n\nCommon Stock\n \nSSII\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\n \n\n \n\n \n\n \n\nAs used in this Current Report on Form 8-K (this “**Current\nReport**”), the terms “**SSi**,” “**the Company**,” “**we**,” “**us**”\nand “**our**” refer to SS Innovations International, Inc. and its subsidiaries.\n\n \n\nI**tem 5.02 Departure of Directors or Certain\nOfficers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\n**Appointment of new Chief\nFinancial Officer**\n\n** **\n\nOn July 14, 2026, we issued a press release announcing\nthe appointment of Sarah M. Romano as the Company’s new Chief Financial Officer, effective August 3, 2026. Ms. Romano will be based\nin the United States. A copy of the press release is attached as **Exhibit 99.1** to this Current Report and is incorporated\nherein by reference.\n\n \n\nMs. Romano, 46, has over two decades of experience\nas a financial professional. Prior to joining the Company, from April 2025 to July 2026, Ms. Romano served as the Chief Financial\nOfficer and Treasurer of Vicarious Surgical Inc. (NYSE/OTCQB: RBOT), a robotic surgery company developing next-generation minimally invasive\nsurgical technology. She previously served as Chief Financial Officer of Entero Therapeutics, Inc. (Nasdaq: ENTO) (formerly First Wave\nBioPharma), a clinical-stage biopharmaceutical company specializing in the development of targeted, orally delivered therapies for gastrointestinal\ndiseases, from March 2022 to March 2025. Prior thereto, she served as Chief Financial Officer of Kiora Pharmaceuticals, Inc. (Nasdaq:\nKPRX) (formerly EyeGate Pharmaceuticals, Inc.), a clinical-stage specialty pharmaceutical company developing products for treating ophthalmic\ndiseases, from February 2017 through February 2022, and as its Corporate Controller from August 2016 to January 2017. Ms. Romano began\nher career as an auditor in the Boston office of PricewaterhouseCoopers. A licensed CPA in Massachusetts, she holds a Bachelor of Arts\nin Accounting from College of the Holy Cross and a Master of Accounting from Boston College.\n\n \n\nThe Company and Ms. Romano entered into a three-year\nemployment agreement, effective August 3, 2026 (the “**Employment Agreement**”), providing for annual base compensation\nof $440,000. Ms. Romano will be eligible for an annual cash bonus based on achievement of certain performance criteria and subject to\nthe terms of the Employment Agreement. In addition, the Employment Agreement provides for Ms. Romano to receive a grant of options under\nthe Company’s 2026 Incentive Stock Plan (the “**Incentive Plan**”) to purchase 750,000 shares of the Company’s\ncommon stock vesting as to 250,000 shares on the first anniversary of the effective date and thereafter in twenty-three (23) installments\nof 20,833 shares, and a final monthly installment of 20,841 shares, subject to continued employment of Ms. Romano by the Company and the\nother terms and conditions of the Incentive Plan. The Employment Agreement also contains customary confidentiality, assignment of proprietary\nrights, non-competition and non-solicitation provisions.\n\n \n\nIn addition to the foregoing, on the effective date of the Employment\nAgreement the Company will enter into an indemnification agreement with Ms. Romano in the form of Exhibit A to the Employment Agreement.\n\n \n\nThe above summary of the Employment Agreement\nis qualified in its entirety by reference to the Employment Agreement, a copy of which is attached as **Exhibit 10.1** to this Current\nReport and is incorporated herein by reference.\n\n \n\n1"}